Tenax Therapeutics announced that its experimental heart failure drug, Levosimendan, did not meet the primary endpoints in a pivotal Phase 3 trial. The drug was being evaluated for treating heart failure with preserved ejection fraction (HFpEF) associated with pulmonary hypertension. The failure casts doubt on the company's near term commercial prospects and sends shares plummeting.
Tenax Therapeutics disclosed on Tuesday that its lead drug candidate, Levosimendan, failed to demonstrate efficacy in a Phase 3 trial evaluating its use in patients with heart failure with preserved ejection fraction (HFpEF) complicated by pulmonary hypertension. The study, which enrolled 350 patients across multiple sites, was designed to assess the drug's impact on reducing pulmonary vascular resistance and improving exercise capacity.
The company had positioned Levosimendan as a potential breakthrough for a patient population with limited treatment options. HFpEF accounts for nearly half of all heart failure cases, and current therapies primarily focus on symptom management rather than addressing the underlying pathophysiology. Pulmonary hypertension in these patients significantly worsens prognosis and quality of life.
DISCUSSION (0)